TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41504

Peptide_Name

FLAK93

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 5-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KWKLF-NH2

FASTA

>TPDB41504|Anticancer|length=5
KWKLF-NH2

Formula C38H56N8O6

Absent Amino Acids ARNDCEQGHIMPSTYV

Common Amino Acids K

Mass 720.91

PI 10.60

Basic Residues 2

Acidic Residues 0

Hydrophobic Residues 3

Net Charge +2

Boman Index -1.56

Hydrophobicity -0.420

Aliphatic Index 78.00

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 762.92

Polar Residues 0

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

1

L

2

K

0

M

1

F

0

P

0

S

0

T

1

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 2 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0

Length

5

Formula

C38H56N8O6

Mass

720.91

PI

10.60

Net Charge

+2

Boman Index

-1.56

Hydrophobicity

-0.420

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

FLAK peptides

Evidence 1 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =600 µg/ml

Detail Source Activity Anticancer

Activity Measurement 600 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =555 µg/ml

Detail Source Activity Anticancer

Activity Measurement 555 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 3 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =>1000 µg/ml

Detail Source Activity Anticancer

Activity Measurement >1000 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 4 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =>1000 µg/ml

Detail Source Activity Anticancer

Activity Measurement >1000 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 5 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =>1000 µg/ml

Detail Source Activity Anticancer

Activity Measurement >1000 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 6 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 = >1000 µg/ml

Detail Source Activity Anticancer

Activity Measurement >1000 µg/mL

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2